Ascletis Pharma Inc. Announces Presentation of ASC30 Clinical Trial Results at 61st EASD Annual Meeting

Reuters

2025/09/02

<a href="https://laohu8.com/S/ASCLF">Ascletis Pharma Inc.</a> Announces Presentation of ASC30 Clinical Trial Results at 61st EASD Annual Meeting

Ascletis Pharma Inc. has announced that it will present the results of its 28-day multiple ascending dose study of the oral small molecule GLP-1 receptor agonist, ASC30, at the upcoming 61st European Association for the Study of Diabetes (EASD) Annual Meeting. The presentation, scheduled for September 16, 2025, in Vienna, Austria, will feature data from a U.S. Phase Ib clinical study and is part of a short oral discussion within the session titled "The GLP-1 portfolio: diverse formulations for expanding clinical applications." This development aims to highlight ASC30's potential in achieving superior weight loss in participants with obesity. Ascletis is also on track to report topline data from a Phase IIa clinical study of ASC30 in the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564096808"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564096808\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564096808?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 17:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564096808","market":"us","top_or_hot":-1,"title":"Ascletis Pharma Inc. Announces Presentation of ASC30 Clinical Trial Results at 61st EASD Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> Announces Presentation of ASC30 Clinical Trial Results at 61st EASD Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ascletis Pharma Inc. has announced that it will present the results of its 28-day multiple ascending dose study of the oral small molecule GLP-1 receptor agonist, ASC30, at the upcoming 61st European Association for the Study of Diabetes (EASD) Annual Meeting. The presentation, scheduled for September 16, 2025, in Vienna, Austria, will feature data from a U.S. Phase Ib clinical study and is part of a short oral discussion within the session titled \"The GLP-1 portfolio: diverse formulations for expanding clinical applications.\" This development aims to highlight ASC30's potential in achieving superior weight loss in participants with obesity. Ascletis is also on track to report topline data from a Phase IIa clinical study of ASC30 in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Inc. Announces Presentation of ASC30 Clinical Trial Results at 61st EASD Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Inc. Announces Presentation of ASC30 Clinical Trial Results at 61st EASD Annual Meeting\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-02 17:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> Announces Presentation of ASC30 Clinical Trial Results at 61st EASD Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ascletis Pharma Inc. has announced that it will present the results of its 28-day multiple ascending dose study of the oral small molecule GLP-1 receptor agonist, ASC30, at the upcoming 61st European Association for the Study of Diabetes (EASD) Annual Meeting. The presentation, scheduled for September 16, 2025, in Vienna, Austria, will feature data from a U.S. Phase Ib clinical study and is part of a short oral discussion within the session titled \"The GLP-1 portfolio: diverse formulations for expanding clinical applications.\" This development aims to highlight ASC30's potential in achieving superior weight loss in participants with obesity. Ascletis is also on track to report topline data from a Phase IIa clinical study of ASC30 in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物醫藥B類股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL90JfLB:1","article_id":"2564096808","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564096808","pubTimestamp":1756806542,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascletis Pharma Inc. has announced that it will present the results of its 28-day multiple ascending dose study of the oral small molecule GLP-1 receptor agonist, ASC30, at the upcoming 61st European Association for the Study of Diabetes  Annual Meeting. The presentation, scheduled for September 16, 2025, in Vienna, Austria, will feature data from a U.S. Phase Ib clinical study and is part of a short oral discussion within the session titled \"The GLP-1 portfolio: diverse formulations for expanding clinical applications.\" This development aims to highlight ASC30's potential in achieving superior weight loss in participants with obesity. Ascletis is also on track to report topline data from a Phase IIa clinical study of ASC30 in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","01672":"歌礼制药-B","BK1161":"生物科技","BK1515":"抗疫概念"},"translate_title":"歌礼制药公司宣布在第61届EASD年会上展示ASC30临床试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":0.9},"content_text":"Ascletis Pharma Inc. Announces Presentation of ASC30 Clinical Trial Results at 61st EASD Annual Meeting\n    \n\n        Ascletis Pharma Inc. has announced that it will present the results of its 28-day multiple ascending dose study of the oral small molecule GLP-1 receptor agonist, ASC30, at the upcoming 61st European Association for the Study of Diabetes (EASD) Annual Meeting. The presentation, scheduled for September 16, 2025, in Vienna, Austria, will feature data from a U.S. Phase Ib clinical study and is part of a short oral discussion within the session titled \"The GLP-1 portfolio: diverse formulations for expanding clinical applications.\" This development aims to highlight ASC30's potential in achieving superior weight loss in participants with obesity. Ascletis is also on track to report topline data from a Phase IIa clinical study of ASC30 in the fourth quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}